Amplification of the MYCN gene is one of the few indicators of poor prognosis in neuroblastoma, and MYCN amplification is common in individuals with high-risk NB, accounting for roughly 20% of primary NB (Schnepp and Maris, 2013). This evidence concerns the gene MYCN and neuroblastoma.